Introduction {#S0001}
============

Amyloid light chain (AL) amyloidosis is a life-threatening protein deposition disease and the most common type of systemic amyloidosis.[@CIT0001] Pathologically, AL amyloidosis is characterized by the accumulation of monoclonal light chain in multiple organs as amyloid fibrils, predominantly in the kidney, liver, peripheral nerves and heart.[@CIT0002] Clinically, it has an insidious onset and is difficult to recognize at an earlier stage. Once the symptoms become evident, visceral damage is usually irreversible, eventually leading to severe organ damage and shortens survival.[@CIT0003] So early diagnosis and targeted therapy of this cancer are essential for AL amyloidosis patients and to get a better prognosis. As for the early diagnosis of AL amyloidosis, amyloid deposition is the most widely used biomarker, but it is required invasive organ biopsy for HE staining, Congo red staining, and electron microscopy.[@CIT0004] Moreover, the molecular mechanism of AL amyloidosis occurrence and progression remains unclear. Therefore, it will be worthwhile to uncover the AL amyloidosis etiology for the purpose of identifying new molecular biomarkers and discovering potential molecular agents.

The gene expression array platform for the analysis of differentially expressed genes (DEGs) is particularly valuable as a molecular technique with significant clinical applications: from molecular diagnosis to classification of cancer typing, from risk stratification to prognosis evaluation, from the discovery of potential molecular agents discovery to the predication of treatment response.[@CIT0005],[@CIT0006] With the wide application of gene chips technique, gene expression profiling studies on myeloma and AL amyloidosis have been performed in the last several years using microarray technology, and most of the microarray data have been deposited in public datasets. Re-analyzing these public data can provide valuable clues for new studies. Many comparative analyses of the DEGs have been carried out on cancers in recent years.[@CIT0007]--[@CIT0009] However, none of the aforementioned studies has been completely investigated in AL amyloidosis.

In this work, we have downloaded the original data (GSE73040) from NCBI Gene Expression Omnibus ([<http://www.ncbi.nlm.nih.gov/geo/>]{.ul}) and reanalyzed them using bioinformatics approaches, which employ powerful statistical methods,[@CIT0010] including identification of DEGs in AL amyloidosis, gene ontology and pathway enrichment analysis with DAVID ([<https://david.ncifcrf.gov/>]{.ul}), integration of DEGs PPI network ([<http://string-db.org>]{.ul}), and discovery of small molecules with cMAP ([[https://portals. broadinstitute.org/cmap](https://portals.broadinstitute.org/cmap)]{.ul}). Subsequently, we provided the novel insight of AL amyloidosis progression at the molecular level, and also identified the candidate genes for diagnosis, prognosis, and therapeutic targets.

Methods {#S0002}
=======

Affymetrix Microarray Data {#S0002-S2001}
--------------------------

The microarray data of GSE73040 were downloaded from GEO datasets. GSE73040, which was based on Agilent GPL6244 platform, was submitted by Paiva et al[@CIT0011] GSE73040 dataset contained 14 samples, including 5 Control samples and 9 amyloidosis samples.

Data Preprocessing and DEGs Screening {#S0002-S2002}
-------------------------------------

The robust multi-array average (RMA) algorithm in affy package was applied to preprocess the raw expression data in the R package.[@CIT0012],[@CIT0013] Then, the limma package in R software was used to identify DEGs between AL amyloidosis and control samples,[@CIT0014] with the statistical significance of *p \<* 0.05 and the fold change \>2.

Gene Ontology and Pathway Enrichment Analysis of DEGs {#S0002-S2003}
-----------------------------------------------------

To investigate the functional pathways of AL amyloidosis, Database for Annotation, Visualization and Integrated Discovery (DAVID) was applied to perform the GO analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis of DEGs.[@CIT0015] *p* \< 0.05 was chosen as the cut-off value for enriched functional pathways.

Integration of PPI Network and Module Analysis {#S0002-S2004}
----------------------------------------------

Firstly, Search Tool for the Retrieval of Interacting Genes (STRING) analysis was performed to investigate DEGs-encoded proteins and PPI.[@CIT0016] The combined score of \>0.4 was considered as the threshold for significant protein pairs. Then, cytoscape was utilized for visualization and calculate the capabilities of the PPI network under default parameters.[@CIT0017] Thirdly, the Network Analyzer plug-in was utilized to calculate the degree score of hub genes. To investigate more specific regulatory relationship of proteins, we performed the module analysis of the PPI network by using the MCODE with default setting.[@CIT0018]

Identification of Small Molecular Agents {#S0002-S2005}
----------------------------------------

The Connectivity Map (cMap) database provides a systematic method for discovering connections between small molecular agents and diseases.[@CIT0019] The query signature in the CMAP dataset is a list of up-regulated and down-regulated genes, then, the DEGs in the PPI network were mapped onto the cMap database. The \|connectivity score\| \> 0.8 was used as the cut-off value to identify candidate small molecular agents. So the identified agents would be forcefully correlated with the query signature, indicating their potential action with AL amyloidosis.

qRT-PCR {#S0002-S2006}
-------

Total RNA was extracted from plasma cells with TRIzol reagent (Life Technologies, USA). For mRNA detection, each RNA sample was revere-transcribed into cDNA using the reverse transcription kit (Takara, Japan). qRT-PCR was performed to detect the levels of mRNA using the comparative Ct method. GAPDH was chosen as the internal control for mRNA.

Statistical Analysis {#S0002-S2007}
--------------------

The expression differences between two groups were analyzed by unpaired *t*-test. Data were presented as mean ± SE. The data were analyzed by SPSS 22.0 software, and visualized by GraphPad Prism 6.0. Moreover, a *p-*Value \< 0.05 was considered to be statistically significant.

Results {#S0003}
=======

DEGs Between the AL Amyloidosis and Control Groups {#S0003-S2001}
--------------------------------------------------

In total, 1464 genes were identified to be differentially expressed genes, including 727 up-regulated genes and 737 down-regulated genes in AL amyloidosis. As shown in the heatmap ([Figure 1](#F0001){ref-type="fig"}), DEGs were divided into 2 clusters according to the clustering analysis result. Meanwhile, normal and AL amyloidosis specimens were also classified into 2 different groups.Figure 1Heatmap and clustering analysis of DEGs. Red: high expression level; Blue: low expression level.

Gene Enrichment and Pathways Analysis of DEGs {#S0003-S2002}
---------------------------------------------

To explore the specific function pattern of DEGs, functional enrichment analysis was performed by DAVID. GO analysis revealed that up-regulated DEGs were mainly significantly enriched in biological processes, including rRNA processing, mitochondrial translational elongation and termination; the down-regulated DEGs were mainly enriched in biological processes, including immune response, regulation of immune response and leukocyte migration. For molecular function, the up-regulated DEGs were enriched in poly (A) RNA binding, structural constituent of ribosome and unfolded protein binding; the down-regulated DEGs were enriched in RAGE receptor binding, protein binding and receptor activity. Additionally, GO cell component analysis showed that the DEGs were significantly enriched in the nucleolus, mitochondrion, plasma membrane and extracellular region ([Table 1](#T0001){ref-type="table"}).Table 1Top Five Enriched GO of Downregulated DEGs and Upregulated DEGsCategoryTermCourtP-value**Up-regulated** GOTERM_BP_DIRECTGO:0006364\~rRNA processing261.15E-07 GOTERM_BP_DIRECTGO:0070125\~mitochondrial translational elongation146.95E-06 GOTERM_BP_DIRECTGO:0070126\~mitochondrial translational termination147.93E-06 GOTERM_BP_DIRECTGO:0000462\~maturation of SSU-rRNA from tricistronic rRNA transcript77.16E-04 GOTERM_BP_DIRECTGO:0031167\~rRNA methylation50.001446088 GOTERM_MF_DIRECTGO:0044822\~poly(A) RNA binding873.22E-12 GOTERM_MF_DIRECTGO:0003735\~structural constituent of ribosome223.23E-05 GOTERM_MF_DIRECTGO:0051082\~unfolded protein binding141.13E-04 GOTERM_MF_DIRECTGO:0008168\~methyltransferase activity110.001551709 GOTERM_MF_DIRECTGO:0070182\~DNA polymerase binding40.005574465 GOTERM_CC_DIRECTGO:0005730\~nucleolus601.34E-07 GOTERM_CC_DIRECTGO:0005654\~nucleoplasm1413.06E-07 GOTERM_CC_DIRECTGO:0005739\~mitochondrion804.68E-07 GOTERM_CC_DIRECTGO:0005737\~cytoplasm2259.23E-06 GOTERM_CC_DIRECTGO:0032040\~small-subunit processome91.63E-05**Down-regulated** GOTERM_BP_DIRECTGO:0006955\~immune response478.12E-11 GOTERM_BP_DIRECTGO:0050776\~regulation of immune response255.77E-08 GOTERM_BP_DIRECTGO:0006954\~inflammatory response381.17E-07 GOTERM_BP_DIRECTGO:0050900\~leukocyte migration201.41E-07 GOTERM_BP_DIRECTGO:0007165\~signal transduction801.77E-07 GOTERM_MF_DIRECTGO:0050786\~RAGE receptor binding62.49E-05 GOTERM_MF_DIRECTGO:0005515\~protein binding3662.08E-04 GOTERM_MF_DIRECTGO:0004872\~receptor activity204.07E-04 GOTERM_MF_DIRECTGO:0032395\~MHC class II receptor activity50.001758722 GOTERM_MF_DIRECTGO:0005089\~Rho guanyl-nucleotide exchange factor activity100.001954932 GOTERM_CC_DIRECTGO:0009897\~external side of plasma membrane366.86E-14 GOTERM_CC_DIRECTGO:0005886\~plasma membrane2322.76E-13 GOTERM_CC_DIRECTGO:0070062\~extracellular exosome1739.96E-13 GOTERM_CC_DIRECTGO:0005887\~integral component of plasma membrane895.06E-07 GOTERM_CC_DIRECTGO:0042613\~MHC class II protein complex88.82E-06

Moreover, the KEGG pathway enrichment analysis by up-regulated DEGs and down-regulated DEGs was listed in [Table 2](#T0002){ref-type="table"}. Among them, the top three up-regulated DEGs were enriched in ribosome biogenesis in eukaryotes, metabolic pathways and ribosome, while the down-regulated DEGs were enriched in hematopoietic cell lineage, tuberculosis, staphylococcus aureus infection and cell adhesion molecules (CAMs).Table 2The Top Five Enriched KEGG Pathways of DEGsKEGG PathwayCourtP-valueGenes**Upregulated** hsa03008:Ribosome biogenesis in eukaryotes115.42E-04IMP3, FBL, RPP25, EMG1, UTP18, TCOF1, POP1, RPP25L, IMP4, RPP40, PWP2 hsa01100:Metabolic pathways609.93E-04GNPDA1, CNDP2, MAN1B1, PIP5K1C, PSPH, PMVK, CMBL, MTHFD1, ST3GAL6, SPR, NDUFS3, PCYT2, COX17, ATP5H, IDUA, PTDSS2, QDPR, POLR1A, NDUFA13, POLR1C, POLR1B, COQ5, COQ3, ADO, MGAT3, NME2, CHSY3, NME1, PLA2G6, MTAP, PYCRL, EXTL3, POLR2L, POLR2I, AASS, EXTL2, PPAT, TK2, THTPA, ISYNA1, CBR1, CYP27B1, ATIC, PAFAH1B3, ENO3, UCK1, GALNT12, GALNT13, PNLIPRP3, NDUFA8, CYP21A2, AMACR, AK9, AMDHD1, PLA2G4A, B3GAT3, NDUFV1, PHGDH, GAMT, CYP2R1 hsa03010:Ribosome130.001703152MRPL24, MRPL4, RPS19, MRPS18C, MRPL21, MRPL27, RPL22, MRPL17, MRPS12, RPLP1, MRPL36, RPS9, MRPL32 hsa00240:Pyrimidine metabolism100.005924413NME2, POLR2L, NME1, POLR2I, POLR1A, POLR1C, UCK1, POLR1B, TK2, AK9 hsa03020:RNA polymerase50.020116138POLR2L, POLR2I, POLR1A, POLR1C, POLR1B**Down-regulated** hsa04640:Hematopoietic cell lineage286.43E-17ITGAM, IL1R1, CD8A, GYPA, MME, ANPEP, IL7R, CD9, CD44, DNTT, IL4R, CD22, HLA-DRB5, CSF3R, CD4, CD5, CR1, CD3G, CR2, CD3D, CD38, CD19, CD36, ITGA6, ITGA5, CD33, CD14, HLA-DRA hsa05152:Tuberculosis285.33E-09ITGAM, ITGB2, BID, TLR1, HLA-DMB, TLR6, HLA-DMA, CD74, NOD2, IL23A, ITGAX, IL10RA, FCER1G, HLA-DRB5, HLA-DPB1, ATP6V0D1, FCGR3A, SYK, CR1, CAMP, CREBBP, HLA-DQA2, LAMP1, PLK3, HLA-DPA1, FCGR2A, CD14, HLA-DRA hsa05150:Staphylococcus aureus infection153.31E-08ITGAL, C5AR1, FPR1, ITGB2, HLA-DMB, HLA-DMA, HLA-DQA2, ITGAM, HLA-DRB5, HLA-DPA1, FCGR2A, HLA-DPB1, CFD, FCGR3A, HLA-DRA hsa04514:Cell adhesion molecules (CAMs)231.12E-07ITGAL, PTPRC, CD8A, SELL, ICAM2, CD99, CDH1, ITGB2, HLA-DMB, HLA-DMA, HLA-DQA2, ITGAM, ITGA6, ICOS, CD58, CD22, HLA-DRB5, CD4, VCAN, HLA-DPA1, HLA-DPB1, CD226, HLA-DRA hsa04145:Phagosome233.02E-07OLR1, NCF2, TUBB2A, NCF4, ITGB2, HLA-DMB, TLR6, HLA-DMA, HLA-DQA2, ITGAM, LAMP1, CD36, ITGA5, HLA-DRB5, HLA-DPA1, FCGR2A, HLA-DPB1, FCGR3A, ATP6V0D1, TUBA1A, CD14, TUBB4A, HLA-DRA

Construction of PPI Network and Sub-Network {#S0003-S2003}
-------------------------------------------

By integrating DEG pairs with combined score \>0.4, PPI network was constructed according to the STRING and visualized in Cytoscape, involving 1270 nodes (DEGs) and 7818 edges ([Figure 2](#F0002){ref-type="fig"}), accounting for 86.74% of all DEGs. As is shown in [Figure 3](#F0003){ref-type="fig"}, the topology property of the PPI network indicates that the node degree distribution of the PPI network was in power-law distribution ([Figure 3](#F0003){ref-type="fig"}). Based on the connectivity degree in the giant network, the numbers of PPI pairs that the gene/protein possessed were screened. In our study, we identified 5 critical nodal genes, such as *ITGAM* (degree, 129), *ITGB2* (degree, 103), *ITGAX* (degree, 94), *IMP3* (degree, 62) and *FBL* (degree, 62), which might participate in AL amyloidosis progression.Figure 2The giant network consisting of 1270 nodes and 7818 edges was extracted from the whole PPI network. Key nodes in the giant network are highlighted in different colors: red corresponds to the up-regulated gene and green corresponds to the down-regulated gene in AL amyloidosis.Figure 3The topology parameters were analyzed according to the giant networks. (**A**) Degree distribution; (**B**) average clustering coefficient; (**C**) shortest path distribution; (**D**) closeness centrality.

Moreover, biological network consists of several functional modules in which these components of the complex and interactions generally lead to the same biological process. We extracted several modules from the PPI network using MCODE analysis. The most highly connected sub-network (cluster rank 1; Score 26.741) was obtained from PPI network complex ([Figure 4A](#F0004){ref-type="fig"}), consisting of 28 nodes and 361 interactions (in which *IMP3* and *FBL* were involved). Another sub-network (cluster rank 3; Score 17.537) was obtained from PPI network complex ([Figure 4B](#F0004){ref-type="fig"}), consisting of 96 nodes and 833 interactions (in which *ITGAM, PTPRC, ITGB2* and *ITGAX* were enriched). Accordingly, for the genes identified in this PPI sub-network, a total of 20 KEGG pathways were enriched ([Table 3](#T0003){ref-type="table"}). The top two pathways were Hematopoietic cell lineage and Primary immunodeficiency.Table 3The Statistically Significant Sub-Pathways Identified by DEGs (Top 5)KEGG PathwayCourtP-valueHematopoietic cell lineage167.0E-15Primary immunodeficiency87.1E-8Cell adhesion molecules (CAMs)101.1E-5Cytokine-cytokine receptor interaction121.0E-4Chemokine signaling pathway99.0E-4 Figure 4The significant module was extracted from the giant network: (**A**) red corresponds to the up-regulated gene; (**B**) green corresponds to the down-regulated gene in NEC.

We utilized the qRT-PCR to detect the expression of key genes in AL amyloidosis patients. As shown in [Figure 5A](#F0005){ref-type="fig"} and [B](#F0005){ref-type="fig"}, the expression of *FBL* and *IMP3* were up-regulated in AL amyloidosis patients compared with healthy control, while the expression of *ITGAM, ITGB2* and *ITGAX* in AL amyloidosis were all lower than healthy controls. These results will support FBL and IMP3 as the biomarker of AL amyloidosis.Figure 5The expression of key genes in AL amyloidosis patients' clonal plasma cells. (**A**) *FBL* and *IMP3* were up-regulated in AL amyloidosis patients compared with healthy control; (**B**) *ITGAM*, *ITGB2*  and *ITGAX* were down-regulated in AL amyloidosis patients compared with healthy control.

Identification of Small Molecular Agents {#S0003-S2004}
----------------------------------------

Based on the results of cMap database mapping, we found several small molecular agents from the cMap database that were potentially correlated to AL amyloidosis. As showed in [Table 4](#T0004){ref-type="table"}, the top 5 small molecular agent were selected according to rank and score, indicating their relatively significant correlation with AL amyloidosis, such as AT-9283, Ritonavir, Indirubin, PKC beta-inhibitor and Cholic-acid.Table 4The Small Molecular Agents Identified of DEGs (Top 5)RankScoreNameDescription192.98AT-9283JAK inhibitor291.39RitonavirHIV protease inhibitor391.27IndirubinCDK inhibitor490.34PKC beta-inhibitorPKC inhibitor588.12Cholic-acidBile acid

Discussion {#S0004}
==========

In our study, a total of 1464 DEGs, including 727 up-regulated genes and 737 down-regulated genes were identified between the AL amyloidosis and control groups. These up-regulated genes were mainly enriched in several functional terms such as positive regulation of mitochondrion, ribosome and unfolded protein binding. As we all know, ribosome and mitochondrion play a vital role in protein synthesis by protein translation and are also essential for cell growth, proliferation, and development.[@CIT0020],[@CIT0021] Down-regulated genes were mainly enriched in several functional terms such as hematopoietic cell lineage, RAGE receptor binding and immune response. RAGE receptor has been shown to contribute to several chronic diseases such as diabetes, amyloidosis, inflammatory conditions.[@CIT0022] Then, PPI network was constructed and several hub genes were identified. According to the analysis of the PPI network, the highly connected module was identified and five hub genes were selected as candidate genes, including *IMP3, FBL, ITGAM, ITGB2* and *ITGAX*. Among the five genes, *IMP3* and *FBL* were enriched in ribosome biogenesis, while *ITGAM, ITGB2* and *ITGAX* might be involved in hematopoietic cell lineage and immune response.

Ribosome biogenesis is a multistage process that involves transcriptional and posttranscriptional regulation, and it is over activated in cancer cells.[@CIT0023],[@CIT0024] In our study, overexpression *IMP3* and *FBL* gene was accordant with GO/KEGG pathway analysis (hsa03008: Ribosome biogenesis in eukaryotes). *IMP3* and *FBL* gene expression are higher in AL amyloidosis than normal samples, which may suggest that overexpression *IMP3* and *FBL* play effect in cancer ribosomes development. In addition, previous study reported that IMP3 was an RNA-binding protein required for ribosomal RNA processing, which was chosen as a prognostic marker in a number of human types of cancer.[@CIT0025],[@CIT0026] The overexpression of FBL contributes to tumorigenesis and is related to poor survival in patients with cancer.[@CIT0027] High expression of FBL was accompanied by modifications of the rRNA methylation pattern, impairment of translational fidelity, and an increase of internal ribosome entry site-dependent translation initiation of key cancer genes.[@CIT0028] Additionally, P53 is involved in FBL regulation and suppresses the expression of the rRNA methyl-transferase fibrillarin by binding directly to FBL.[@CIT0028],[@CIT0029] In summary, molecular signature of AL amyloidosis consists of 23 genes representing mainly ribosomal proteins, and these signatures appear pathogenetically supported the effect of ribosome dysfunction in AL amyloidosis.

Hematopoietic cell lineage is the progress of hematopoietic stem cell undergo either self-renewal or differentiation into a multilineage committed progenitor cells. In our study, the down-regulated DEGs were significantly enriched in hematopoietic cell lineage and immune response, which weakened these pathways about hematopoietic and immunologic function, were conducive to tumor progression. The top four down-regulated genes with the highest degrees in the PPI network were *ITGAM (CD11b), PTPRC (CD45), ITGB2 (CD18)* and *ITGAX (CD11c)*. Theses aberrant expression of antigens may play a vital role in regulating immune responses in AL amyloidosis patients. Zhu et al have successfully detected the CD45 deficiency drives Amyloid-β Peptide Oligomers and accelerates cerebral amyloidosis.[@CIT0030] However, no studies focus on CD11b, CD18 and CD11c in AL amyloidosis. Compose complement receptor type 3 (CR3, comprising CD11b/CD18) and type 4 (CR4, comprising CD11c/CD18) belong to the family of β2 integrins, and act as control points in immunity and cancer.[@CIT0031] For instance, by interaction with iC3b, CR3 and CR4 mediate the uptake of opsonized cells and particles by macrophages, neutrophils, monocytes and dendritic cells;[@CIT0032] by interaction with ICAM1, ICAM4 and LFA1, CR3 and CR4 serve the important task of the formation of the immunological synapse, crucial the contact between antigen presenting cells and T lymphocytes.[@CIT0033]--[@CIT0035] Furthermore, a former study showed that pharmacological activation of CD11b/CD18 could promote pro-inflammatory macrophage polarization and suppress tumor growth in animal models of murine and human cancer.[@CIT0036] CR3 and CR4 were proved to enable complement-dependent cell cytotoxicity toward antibody-coated tumor cells as part of biological therapy.[@CIT0037] As revealed in our sub-network, KEGG pathways were also predicted correlations with the hematopoietic cell lineage and immunodeficiency, providing a clue that *ITGAM, ITGB2* and *ITGAX* might also be involved in AL amyloidosis progression via regulating immune response.

Furthermore, the study found candidate small molecules that may be involved in promoting or suppressing the development of AL amyloidosis. AT-9283 was identified to be small molecular agents with the highest score, which has been reported that AT-9283 significantly inhibits myeloma cell growth and promotes apoptosis in vivo and vitro.[@CIT0038] Another molecule, Enzastaurin (PKC beta-inhibitor) is an oral serine/threonine kinase inhibitor of the protein kinase C and phosphatidylinositol 3 kinase/Akt pathways that promote apoptosis of myeloma cells in a caspase-independent manner.[@CIT0039] Two Phase II trials were designed to explore the efficacy of AT-9283 (NCT01145989) and Enzastaurin (NCT00718419) in patients with multiple myeloma.[@CIT0040],[@CIT0041] Additionally, ritonavir could increase the level of endoplasmic reticulum stress in myeloma cells, which sensitizes bortezomib-resistant cells to bortezomib-induced apoptosis.[@CIT0042] Importantly, MM have previously been administered these small molecular agents, strongly supporting the investigation of repurposing AT-9283, Enzastaurin and ritonavir for AL amyloidosis therapy.

Conclusion {#S0005}
==========

Taken together, our study has identified several candidate genes (*ITGAM, ITGB2, ITGAX, IMP3* and *FBL*) that were involved in the mechanism of AL amyloidosis, and *IMP3* and *FBL* play essential roles in dysfunction of Ribosome biogenesis. Besides, *ITGAM, ITGB2* and *ITGAX* are crucial for hematopoietic cell lineage and immune response to AL amyloidosis occurrence and progression. Furthermore, AT-9283, Enzastaurin and ritonavir may act as potential molecular drugs for AL amyloidosis treatment. Our results provide better understanding of AL amyloidosis pathogenesis. Further research of these candidate genes and therapeutic agents are urgently needed to determine their effects in AL amyloidosis.
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